Bay Area Cancer Research Group, LLC

Pleasant Hill, California 94523

0 studies enrolling now · 12 studies all time

What they study most

Breast Cancer, Carcinoma, Non-small Cell, Carcinoma, Renal Cell, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma, Non Small Cell Lung Cancer (NSCLC), Non-Hodgkin's Lymphoma, Non-small Cell Lung Cancer, Pancreatic Cancer

Studies at this site

• Connect® MM- The Multiple Myeloma Disease Registry — Stopped early
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. — Completed
• A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) — Completed
• A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer — Completed
• Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung — Completed
• Study of PX-866 and Docetaxel in Solid Tumors — Completed
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer — Completed
• A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer — Completed
• An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia — Completed
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed
• A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer — Completed
• APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer — Completed